The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer
Open accessAbstract
BACKGROUND: Between 1999 and 2009 in the United Kingdom, 82,429 men between 50 and 69 years of age received a prostate-specific antigen (PSA) test. Localized prostate cancer was diagnosed in 2664 men. Of these men, 1643 were enrolled in a trial to evaluate the effectiveness of treatments, with 545 randomly assigned to receive active monitoring, 553 to undergo prostatectomy, and 545 to undergo radiotherapy. METHODS: At a median follow-up of 15 years (range, 11 to 21), we compared the results in this population with respect to death from prostate cancer (the primary outcome) and death from any cause, metastases, disease progression, and initiation of long-term androgen-deprivation therapy (secondary outcomes). RESULTS: Follow-up was complete for 1610 patients (98%). A risk-stratification analysis showed that more than one third of the men had intermediate or high-risk disease at diagnosis. Death from prostate cancer occurred in 45 men (2.7%): 17 (3.1%) in the active-monitoring group, 12 (2.2%) in the prostatectomy group, and 16 (2.9%) in the radiotherapy group (P = 0.53 for the overall comparison). Death from any cause occurred in 356 men (21.7%), with similar numbers in all three groups. Metastases developed in 51 men (9.4%) in the active-monitoring group, in 26 (4.7%) in the prostatectomy group, and in 27 (5.0%) in the radiotherapy group. Long-term androgen-deprivation therapy was initiated in 69 men (12.7%), 40 (7.2%), and 42 (7.7%), respectively; clinical progression occurred in 141 men (25.9%), 58 (10.5%), and 60 (11.0%), respectively. In the active-monitoring group, 133 men (24.4%) were alive without any prostate cancer treatment at the end of follow-up. No differential effects on cancer-specific mortality were noted in relation to the baseline PSA level, tumor stage or grade, or risk-stratification score. No treatment complications were reported after the 10-year analysis. CONCLUSIONS: After 15 years of follow-up, prostate cancer-specific mortality was low regardless of the treatment assigned. Thus, the choice of therapy involves weighing trade-offs between benefits and harms associated with treatments for localized prostate cancer. (Funded by the National Institute for Health and Care Research; ProtecT Current Controlled Trials number, ISRCTN20141297; ClinicalTrials.gov number, NCT02044172.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
D'Amico, A. V. (1998) · JAMA · doi:10.1001/jama.280.11.969 · Cited by 4,523
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer
Hamdy, F. C., Donovan, J. L., Lane, J. A., Mason, M., Metcalfe, C., Holding, P., Davis, M., Peters, T. J., Turner, E. L., Martin, R. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606220 · Cited by 2,640
Self-citationScreening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force, Grossman, D. C., Curry, S. J., Owens, D. K., Bibbins-Domingo, K., Caughey, A. B., Davidson, K. W., Doubeni, C. A., Ebell, M., Epling, J. W., et al. (2018) · JAMA · doi:10.1001/jama.2018.3710 · Cited by 1,436
COOPERBERG, M. R., PASTA, D. J., ELKIN, E. P., LITWIN, M. S., LATINI, D. M., Du CHANE, J., & CARROLL, P. R. (2005) · Journal of Urology · doi:10.1097/01.ju.0000158155.33890.e7 · Cited by 772
Radical Prostatectomy or Watchful Waiting in Prostate Cancer — 29-Year Follow-up
Bill-Axelson, A., Holmberg, L., Garmo, H., Taari, K., Busch, C., Nordling, S., Häggman, M., Andersson, S.-O., Andrén, O., Steineck, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1807801 · Cited by 495
Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics
Islami, F., Ward, E. M., Sung, H., Cronin, K. A., Tangka, F. K. L., Sherman, R. L., Zhao, J., Anderson, R. N., Henley, S. J., Yabroff, K. R., et al. (2021) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djab131 · Cited by 478
the ICGC Prostate Group, Cooper, C. S., Eeles, R., Wedge, D. C., Van Loo, P., Gundem, G., Alexandrov, L. B., Kremeyer, B., Butler, A., Lynch, A. G., et al. (2015) · Nature Genetics · doi:10.1038/ng.3221 · Cited by 434
Self-citationSpatially resolved clonal copy number alterations in benign and malignant tissue
Erickson, A., He, M., Berglund, E., Marklund, M., Mirzazadeh, R., Schultz, N., Kvastad, L., Andersson, A., Bergenstråhle, L., Bergenstråhle, J., et al. (2022) · Nature · doi:10.1038/s41586-022-05023-2 · Cited by 303
Self-citationTrends in Incidence of Metastatic Prostate Cancer in the US
Desai, M. M., Cacciamani, G. E., Gill, K., Zhang, J., Liu, L., Abreu, A., & Gill, I. S. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.2246 · Cited by 244
Multiple testing in clinical trials
Bauer, P. (1991) · Statistics in Medicine · doi:10.1002/sim.4780100609 · Cited by 241
Lane, J. A., Donovan, J. L., Davis, M., Walsh, E., Dedman, D., Down, L., Turner, E. L., Mason, M. D., Metcalfe, C., Peters, T. J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70361-4 · Cited by 231
Self-citationWilt, T. J., Vo, T. N., Langsetmo, L., Dahm, P., Wheeler, T., Aronson, W. J., Cooperberg, M. R., Taylor, B. C., & Brawer, M. K. (2020) · European Urology · doi:10.1016/j.eururo.2020.02.009 · Cited by 185
Jemal, A., Culp, M. B., Ma, J., Islami, F., & Fedewa, S. A. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa068 · Cited by 167
Donovan, J., Lane, J. A., Peters, T. J., Brindle, L. A., Salter, E., Gillatt, D. A., Powell, P. H., Bollina, P. R., Neal, D. E., & Hamdy, F. C. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2008.02.010 · Cited by 159
Self-citationPatient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment
Donovan, J., Hamdy, F. C., Lane, J. A., Young, G., Metcalfe, C., Walsh, E. I., Davis, M., Steuart-Feilding, T., Blazeby, J. M., AVERY, K. N. L., et al. (2023) · NEJM Evidence · doi:10.1056/evidoa2300018 · Cited by 123
Self-citationHamdy, F. C., Donovan, J., Lane, J. A., Mason, M. D., Metcalfe, C., Holding, P., Wade, J., Noble, S., Garfield, K., Young, G., et al. (2020) · Health Technology Assessment · doi:10.3310/hta24370 · Cited by 57
Self-citationDonovan, J., Young, G., Walsh, E. I., Metcalfe, C., Lane, J. A., Martin, R. M., Tazewell, M. K., Davis, M., Peters, T. J., Turner, E. L., et al. (2017) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2017.12.019 · Cited by 22
Self-citation
Cited by
Siegel, R. L., Giaquinto, A. N., & Jemal, A. (2024) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21820 · Cited by 9,533
“42 Nevertheless, uptake of active surveillance is slower in the United States compared with other countries, 43 with approximately 40% of men with low ‐ risk disease actively treated in 2021.”
BackgroundCornford, P., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Brunckhorst, O., Darraugh, J., Eberli, D., De Meerleer, G., De Santis, M., Farolfi, A., et al. (2024) · European Urology · doi:10.1016/j.eururo.2024.03.027 · Cited by 1,246
The Lancet Commission on prostate cancer: planning for the surge in cases
James, N. D., Tannock, I., N'Dow, J., Feng, F., Gillessen, S., Ali, S. A., Trujillo, B., Al-Lazikani, B., Attard, G., Bray, F., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00651-2 · Cited by 738
Saha, A., Bosma, J. S., Twilt, J. J., van Ginneken, B., Bjartell, A., Padhani, A. R., Bonekamp, D., Villeirs, G., Salomon, G., Giannarini, G., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00220-1 · Cited by 346
Prostate Cancer, Version 3.2024: Featured Updates to the NCCN Guidelines
Schaeffer, E. M., Srinivas, S., Adra, N., An, Y., Bitting, R., Chapin, B., Cheng, H. H., D’Amico, A. V., Desai, N., Dorff, T., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0019 · Cited by 312
Metadata
- Authors
- Hamdy, F. C., Donovan, J. L., Lane, J. A., Metcalfe, C., Davis, M., Turner, E. L., Martin, R. M., Young, G. J., Walsh, E. I., Bryant, R. J., Bollina, P., Doble, A., Doherty, A., Gillatt, D., Gnanapragasam, V., Hughes, O., Kockelbergh, R., Kynaston, H., Paul, A., Paez, E., Powell, P., Rosario, D. J., Rowe, E., Mason, M., Catto, J. W. F., Peters, T. J., Oxley, J., Williams, N. J., Staffurth, J., & Neal, D. E.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-04-27
- Volume
- 388
- Issue
- 17
- Pages
- 1547-1558
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4323928271
- Cited by
- 823
- References
- 17
- FWCI
- 130.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.